KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 4.15% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $13.0 million, down 5.8%, while the annual FY2025 figure was $13.0 million, 5.8% down from the prior year.
  • Depreciation & Amortization (CF) reached $2.7 million in Q4 2025 per PACB's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.1 million in Q1 2025 and bottomed at $1.6 million in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $2.7 million, with a median of $2.7 million recorded in 2025.
  • The widest YoY moves for Depreciation & Amortization (CF): up 58.36% in 2025, down 41.31% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.3 million in 2021, then grew by 12.67% to $2.5 million in 2022, then grew by 17.03% to $3.0 million in 2023, then dropped by 3.63% to $2.9 million in 2024, then dropped by 4.15% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $2.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.